semaglutide approval mash CDSCO Clears Wegovy for — India's First GLP-1 for Liver Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on Semaglutide, a GLP-1R agonist, is

Developed by leading scientists, we designed a new molecule and combined this with our proprietary formulation into a daily tablet that supports appetite regulation, metabolism, and longevity.* Evolv GLP-1 uses our own proprietary, science-backed ingredient designed to naturally activate GLP-1, a hormone in the body, for extended periods

This only needs to be done before your first injection with each new pen

Understanding the difference helps you have informed conversations with your prescribing physician about which might be appropriate for your situation

Further mechanistic studies were initiated investigating whether SAR425899 targets the GCGR including effects on energy expenditure and amino acid patterns

10.1152/ajplegacy.1930.91.2.649 3